Q3 Earnings Forecast for Zenas BioPharma Issued By Wedbush

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Analysts at Wedbush lowered their Q3 2025 earnings per share estimates for Zenas BioPharma in a research report issued to clients and investors on Thursday, October 9th. Wedbush analyst M. Fan now expects that the company will earn ($0.27) per share for the quarter, down from their prior estimate of $1.91. Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. Wedbush also issued estimates for Zenas BioPharma’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.95) EPS, Q1 2026 earnings at ($1.54) EPS, Q2 2026 earnings at ($1.55) EPS, Q3 2026 earnings at ($1.41) EPS, Q4 2026 earnings at ($1.42) EPS, FY2026 earnings at ($5.90) EPS, FY2027 earnings at ($4.66) EPS, FY2028 earnings at ($4.72) EPS and FY2029 earnings at ($3.23) EPS.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.23).

Several other research analysts have also recently issued reports on ZBIO. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Zenas BioPharma in a research note on Thursday, October 9th. Wall Street Zen cut Zenas BioPharma from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.33.

Zenas BioPharma Stock Down 2.6%

Shares of NASDAQ:ZBIO opened at $25.85 on Monday. Zenas BioPharma has a 52-week low of $5.83 and a 52-week high of $29.73. The stock has a market cap of $1.09 billion and a P/E ratio of -7.28. The business’s 50 day moving average is $19.25 and its 200 day moving average is $13.64.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after acquiring an additional 3,412 shares in the last quarter. Sei Investments Co. acquired a new position in Zenas BioPharma during the 2nd quarter valued at about $118,000. Federated Hermes Inc. increased its position in Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after buying an additional 703,838 shares in the last quarter. Rhumbline Advisers increased its position in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after buying an additional 8,207 shares in the last quarter. Finally, Intech Investment Management LLC increased its position in Zenas BioPharma by 13.9% during the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock valued at $128,000 after buying an additional 1,607 shares in the last quarter.

Insider Transactions at Zenas BioPharma

In related news, Director Hongbo Lu purchased 263,160 shares of Zenas BioPharma stock in a transaction dated Tuesday, October 7th. The stock was purchased at an average cost of $19.00 per share, with a total value of $5,000,040.00. Following the transaction, the director owned 321,983 shares in the company, valued at approximately $6,117,677. The trade was a 447.38% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Fairmount Funds Management Llc purchased 316,219 shares of Zenas BioPharma stock in a transaction dated Tuesday, October 7th. The stock was bought at an average cost of $19.00 per share, with a total value of $6,008,161.00. Following the completion of the transaction, the director owned 2,209,025 shares in the company, valued at approximately $41,971,475. This represents a 16.71% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 923,035 shares of company stock worth $17,628,163. Company insiders own 16.50% of the company’s stock.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.